Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. It is manufactured and marketed under the brand name Strattera® by Eli Lilly and Company. There is currently no generic available within the United States due to patent restrictions; however, a generic is available outside the United States, which is manufactured by Torrent Pharmaceuticals.
Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under 6 years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.
More on [ Atomoxetine ]

Atomoxetine (Strattera) from Eli Lilly - Includes prescribing information, news, and clinical trial information for consumers and U.S. healthcare professionals for this ADHD medication.
Meta Description: [ ReoPro® (Abciximab) is a monoclonal antibody that blocks the pathway to platelet aggregation and reduces cardiac ischemic complications in patients undergoing PCI (percutaneous coronary intervention). ]
MedlinePlus: Atomoxetine - Features information about dosage, usage, warnings, and side effects.
Meta Description: [ Atomoxetine ]
| Risk of Suicidality in Children Treated w Strattera (Dec 05) | |
| Next Video | |